BioCentury | Dec 31, 2020
Politics, Policy & Law

Innovations forged in the COVID crucible will reshape medicine: Editor’s Commentary

The fight against COVID-19 is far from finished, but victory is close enough to start considering how the tools created to tame SARS-CoV2 will reshape the post-war world. As with World War II and the...
BioCentury | Sep 10, 2020
Product Development

Medicxi’s de Rubertis hopes for positive future for infectious disease after COVID-19: a BioCentury audio interview

Francesco de Rubertis, co-founder and partner of Medicxi, is optimistic that the COVID-19 pandemic might lead to an increased interest in infectious disease investment, but it will take government action to create the incentives. de...
BioCentury | May 13, 2020
Emerging Company Profile

QurAlis taking three ALS programs toward clinic with $42M series A

After launching with a modest seed round in 2018, neurology company QurAlis is driving toward the clinic with a $42 million series A round to fund development of three therapies to treat amyotrophic lateral sclerosis...
BioCentury | May 14, 2019
Company News

Management tracks: DBV, Beam, Aeon Biopharma

DBV Technologies S.A. (Euronext:DBV; NASDAQ:DBVT) said Deputy CEO and Principal Financial Officer David Schilansky will leave the company in August to pursue other opportunities. The allergy company is searching for a new CFO but will...
BioCentury | Jul 17, 2018
Distillery Therapeutics

Cancer

INDICATION: Colorectal cancer Mouse studies suggest MAPKAPK2 inhibitors could help treat colorectal cancer. In a mouse model of colorectal cancer, systemic MAPKAPK2 knockout decreased tumor number, tumor volume and intestinal polyps and increased survival compared...
BioCentury | Jun 9, 2018
Product Development

POC for cytokines

A body of clinical evidence is emerging that two different approaches to immune-stimulating cytokine therapies could increase efficacy of PD-1 inhibitors in both hot and cold tumors. Oncologists who spoke to BioCentury said, taken together,...
BioCentury | Dec 19, 2017
Distillery Therapeutics

Ophthalmic disease

INDICATION: Diabetic retinopathy Patient samples and mouse studies suggest inhibiting EPHX2 could help treat non-proliferative diabetic retinopathy (NPDR). In postmortem retinal tissue samples from patients, high levels of EPHX2 were associated with disease severity. In...
BioCentury | Nov 16, 2017
Tools & Techniques

Yeast against aggregation

In drug discovery for neurodegenerative diseases, the emphasis is on finding better models of neuronal systems that recapitulate synapses, neuroinflammation and the pathological accumulation of toxic aggregates. Yumanity Therapeutics LLC and a handful of academic...
BioCentury | Oct 23, 2014
Cover Story

Diagnosing resistance

It might be a day late and a dollar short, but the U.S. government is finally getting around to addressing what many experts think is the big unserved need in antibiotic resistance-new diagnostics. Faster, more...
BioCentury | Sep 22, 2014
Regulation

Pandora's CVOT

Related article: Weighing in on obesity After more than three years and multiple setbacks related to establishing Contrave naltrexone/bupropion's cardiovascular safety, Orexigen Therapeutics Inc. 's obesity drug finally won FDA approval this month. But concerns...
Items per page:
1 - 10 of 114
BioCentury | Dec 31, 2020
Politics, Policy & Law

Innovations forged in the COVID crucible will reshape medicine: Editor’s Commentary

The fight against COVID-19 is far from finished, but victory is close enough to start considering how the tools created to tame SARS-CoV2 will reshape the post-war world. As with World War II and the...
BioCentury | Sep 10, 2020
Product Development

Medicxi’s de Rubertis hopes for positive future for infectious disease after COVID-19: a BioCentury audio interview

Francesco de Rubertis, co-founder and partner of Medicxi, is optimistic that the COVID-19 pandemic might lead to an increased interest in infectious disease investment, but it will take government action to create the incentives. de...
BioCentury | May 13, 2020
Emerging Company Profile

QurAlis taking three ALS programs toward clinic with $42M series A

After launching with a modest seed round in 2018, neurology company QurAlis is driving toward the clinic with a $42 million series A round to fund development of three therapies to treat amyotrophic lateral sclerosis...
BioCentury | May 14, 2019
Company News

Management tracks: DBV, Beam, Aeon Biopharma

DBV Technologies S.A. (Euronext:DBV; NASDAQ:DBVT) said Deputy CEO and Principal Financial Officer David Schilansky will leave the company in August to pursue other opportunities. The allergy company is searching for a new CFO but will...
BioCentury | Jul 17, 2018
Distillery Therapeutics

Cancer

INDICATION: Colorectal cancer Mouse studies suggest MAPKAPK2 inhibitors could help treat colorectal cancer. In a mouse model of colorectal cancer, systemic MAPKAPK2 knockout decreased tumor number, tumor volume and intestinal polyps and increased survival compared...
BioCentury | Jun 9, 2018
Product Development

POC for cytokines

A body of clinical evidence is emerging that two different approaches to immune-stimulating cytokine therapies could increase efficacy of PD-1 inhibitors in both hot and cold tumors. Oncologists who spoke to BioCentury said, taken together,...
BioCentury | Dec 19, 2017
Distillery Therapeutics

Ophthalmic disease

INDICATION: Diabetic retinopathy Patient samples and mouse studies suggest inhibiting EPHX2 could help treat non-proliferative diabetic retinopathy (NPDR). In postmortem retinal tissue samples from patients, high levels of EPHX2 were associated with disease severity. In...
BioCentury | Nov 16, 2017
Tools & Techniques

Yeast against aggregation

In drug discovery for neurodegenerative diseases, the emphasis is on finding better models of neuronal systems that recapitulate synapses, neuroinflammation and the pathological accumulation of toxic aggregates. Yumanity Therapeutics LLC and a handful of academic...
BioCentury | Oct 23, 2014
Cover Story

Diagnosing resistance

It might be a day late and a dollar short, but the U.S. government is finally getting around to addressing what many experts think is the big unserved need in antibiotic resistance-new diagnostics. Faster, more...
BioCentury | Sep 22, 2014
Regulation

Pandora's CVOT

Related article: Weighing in on obesity After more than three years and multiple setbacks related to establishing Contrave naltrexone/bupropion's cardiovascular safety, Orexigen Therapeutics Inc. 's obesity drug finally won FDA approval this month. But concerns...
Items per page:
1 - 10 of 114